Updated on 6 July 2012
Do you have any partnership and alliances to help you in your R&D? If yes, then how are these organizations benefiting by investing in your research?
Yes, we work with a number of sponsoring organisations such as research charities, government bodies and a social enterprise called Optimum Patient Care. Also, we partner with many universities and academics across the world including units in France, Italy, Spain, Portugal, Netherlands, Sweden, Norway, Denmark, Australia, Canada, Malaysia and Vietnam
What do you think are the three most significant achievements and successes of your institutes in the battle against respiratory diseases?
We have had several significant developments in our work in respiratory diseases. Recent work includes UK government-funded research that has shown comparable effectiveness between leukotriene antagonists and inhaled steroids We published the research in the New England Journal of Medicine. Other work published in the Journal of Allergy and Clinical Immunology has shown an association between inhaled steroid particle size and asthma control with small particle formulations provided better outcomes and similar work showing more advanced inhalers providing better results.
What are the R&D programs in your pipeline? What are your objectives for the future?